German herbal medicine veregenr was approved in Israel and other places

The German biopharmaceutical company, medigene AG, has been approved to market the plant medicine veregenr in Israel, Denmark and Slovakia, which is used for the treatment of genital warts Madikin and its partner, azanta, are expected to launch veregenr in Denmark, Norway and Switzerland in early 2013 In the Israeli market, medikin and partner Teva are expected to launch in 2013 Veregenr has been successfully launched in the US (by fougera), Germany and Austria (by Abbott), Spain (by bial) Applications for listing approval in other countries have been approved or are expected to be approved in the next few months Madikin has reached several partnerships in Europe, Asia, the United States and so on, and plans to continue to promote the global authorization strategy Veregenr: it is an external treatment drug for genital warts The main ingredient catechins is extracted from green tea (tea tree) tea It is a concentrate containing catechins and other green tea ingredients It is used to treat genital warts caused by human papillomavirus (HPV) It is the first botanical prescription drug approved by FDA in the United States Genital warts are a common and rapidly spreading venereal disease in the world Benign skin tumors near the genitals and anus are not only damaged in appearance (Jesus Christ), but also infectious and difficult to cure There are 14 million people in North America and about 15 million in Europe who are infected with human papillomavirus (HPV type 6 or 11)).